🚀 VC round data is live in beta, check it out!
Vor Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vor Biopharma and similar public comparables like TYK Medicines, Alto Neuroscience, Zura Bio, LB Pharmaceuticals and more.
Vor Biopharma Overview
About Vor Biopharma
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Founded
2015
HQ
Employees
168
Website
Sectors
Financials (LTM)
EV
$457M
Vor Biopharma Financials
Vor Biopharma reported last 12-month revenue of — and negative EBITDA of ($318M).
In the same LTM period, Vor Biopharma generated — in gross profit, ($318M) in EBITDA losses, and had net loss of ($555M).
Revenue (LTM)
Vor Biopharma P&L
In the most recent fiscal year, Vor Biopharma reported revenue of — and EBITDA of ($369M).
Vor Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($318M) | XXX | ($369M) | XXX | XXX | XXX |
| Net Profit | ($555M) | XXX | ($696M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vor Biopharma Stock Performance
Vor Biopharma has current market cap of $624M, and enterprise value of $457M.
Market Cap Evolution
Vor Biopharma's stock price is $15.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $457M | $624M | 0.0% | XXX | XXX | XXX | $-16.76 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVor Biopharma Valuation Multiples
Vor Biopharma trades at (1.4x) EV/EBITDA.
EV / Revenue (LTM)
Vor Biopharma Financial Valuation Multiples
As of April 6, 2026, Vor Biopharma has market cap of $624M and EV of $457M.
Equity research analysts estimate Vor Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vor Biopharma has a P/E ratio of (1.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $624M | XXX | $624M | XXX | XXX | XXX |
| EV (current) | $457M | XXX | $457M | XXX | XXX | XXX |
| EV/EBITDA | (1.4x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/EBIT | (1.4x) | XXX | (1.2x) | XXX | XXX | XXX |
| P/E | (1.1x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/FCF | (2.6x) | XXX | (3.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vor Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vor Biopharma Margins & Growth Rates
Vor Biopharma's revenue in the last fiscal year grew by —.
Vor Biopharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.2M for the same period.
Vor Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (42%) | XXX | (53%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vor Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TYK Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Alto Neuroscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Zura Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| LB Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Ocugen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vor Biopharma M&A Activity
Vor Biopharma acquired XXX companies to date.
Last acquisition by Vor Biopharma was on XXXXXXXX, XXXXX. Vor Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vor Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVor Biopharma Investment Activity
Vor Biopharma invested in XXX companies to date.
Vor Biopharma made its latest investment on XXXXXXXX, XXXXX. Vor Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vor Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vor Biopharma
| When was Vor Biopharma founded? | Vor Biopharma was founded in 2015. |
| Where is Vor Biopharma headquartered? | Vor Biopharma is headquartered in United States. |
| How many employees does Vor Biopharma have? | As of today, Vor Biopharma has over 168 employees. |
| Who is the CEO of Vor Biopharma? | Vor Biopharma's CEO is Jean-Paul Kress. |
| Is Vor Biopharma publicly listed? | Yes, Vor Biopharma is a public company listed on Nasdaq. |
| What is the stock symbol of Vor Biopharma? | Vor Biopharma trades under VOR ticker. |
| When did Vor Biopharma go public? | Vor Biopharma went public in 2021. |
| Who are competitors of Vor Biopharma? | Vor Biopharma main competitors are TYK Medicines, Alto Neuroscience, Zura Bio, LB Pharmaceuticals. |
| What is the current market cap of Vor Biopharma? | Vor Biopharma's current market cap is $624M. |
| Is Vor Biopharma profitable? | No, Vor Biopharma is not profitable. |
| What is the current EBITDA of Vor Biopharma? | Vor Biopharma has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Vor Biopharma? | Current EBITDA multiple of Vor Biopharma is (1.4x). |
| What is the current FCF of Vor Biopharma? | Vor Biopharma's last 12 months FCF is ($177M). |
| What is the current EV/FCF multiple of Vor Biopharma? | Current FCF multiple of Vor Biopharma is (2.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.